BR112015022044A2 - um método de proporcionar neutroproteção ocular - Google Patents

um método de proporcionar neutroproteção ocular

Info

Publication number
BR112015022044A2
BR112015022044A2 BR112015022044A BR112015022044A BR112015022044A2 BR 112015022044 A2 BR112015022044 A2 BR 112015022044A2 BR 112015022044 A BR112015022044 A BR 112015022044A BR 112015022044 A BR112015022044 A BR 112015022044A BR 112015022044 A2 BR112015022044 A2 BR 112015022044A2
Authority
BR
Brazil
Prior art keywords
neutroprotection
providing ocular
formula
ocular
providing
Prior art date
Application number
BR112015022044A
Other languages
English (en)
Inventor
K Mcvicar William
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of BR112015022044A2 publication Critical patent/BR112015022044A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

resumo "um método de proporcionar neutroproteção ocular" são proporcionados aqui compostos da fórmula i, composições compreendendo uma quantidade eficaz de um composto da fórmula i, e métodos para prevenção, redução, ou tratamento de lesões nas células ganglionares da retina compreendendo administração de uma quantidade eficaz de um derivado de purina a um sujeito com sua necessidade.
BR112015022044A 2013-03-15 2014-03-14 um método de proporcionar neutroproteção ocular BR112015022044A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798412P 2013-03-15 2013-03-15
PCT/US2014/027672 WO2014152733A1 (en) 2013-03-15 2014-03-14 A method of providing ocular neuroprotection

Publications (1)

Publication Number Publication Date
BR112015022044A2 true BR112015022044A2 (pt) 2017-07-18

Family

ID=51529965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022044A BR112015022044A2 (pt) 2013-03-15 2014-03-14 um método de proporcionar neutroproteção ocular

Country Status (12)

Country Link
US (1) US20140275128A1 (pt)
EP (1) EP2968388A4 (pt)
JP (1) JP2016513707A (pt)
KR (1) KR20150138182A (pt)
CN (1) CN105188713A (pt)
AU (1) AU2014239232A1 (pt)
BR (1) BR112015022044A2 (pt)
CA (1) CA2902888A1 (pt)
EA (1) EA201591434A1 (pt)
MX (1) MX2015013240A (pt)
NZ (1) NZ630760A (pt)
WO (1) WO2014152733A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
EA201790851A1 (ru) * 2014-12-03 2017-11-30 Инотек Фармасьютикалз Корпорейшн Способы предотвращения, уменьшения и лечения макулодистрофии
DE102017008072A1 (de) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten
KR102007640B1 (ko) * 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278708A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US20090220516A1 (en) * 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
US20070238694A1 (en) * 2006-03-23 2007-10-11 Inotek Pharmaceuticals Corporation Purine compounds and methods of use thereof
AU2010313544A1 (en) * 2009-10-26 2012-05-10 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
KR20120115344A (ko) * 2010-01-11 2012-10-17 이노텍 파마슈티컬스 코포레이션 안압을 감소시키는 혼합물, 키트 및 방법
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular

Also Published As

Publication number Publication date
KR20150138182A (ko) 2015-12-09
WO2014152733A1 (en) 2014-09-25
CN105188713A (zh) 2015-12-23
EA201591434A1 (ru) 2016-03-31
CA2902888A1 (en) 2014-09-25
MX2015013240A (es) 2016-04-07
AU2014239232A1 (en) 2015-10-01
EP2968388A1 (en) 2016-01-20
JP2016513707A (ja) 2016-05-16
NZ630760A (en) 2017-09-29
EP2968388A4 (en) 2016-10-19
US20140275128A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CO2017011038A2 (es) Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca”
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112013018286A2 (pt) derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
EA201591628A1 (ru) Дейтерированный палбоциклиб
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112015023694A2 (pt) entrega craniana de fármacos
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI